Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
Sign Up to like & getrecommendations! Published in 2025 at "Advanced Science"
DOI: 10.1002/advs.202413209
Abstract: Fibroblast growth factor receptor (FGFR) family aberrations are common in urothelial cancer. The FGFR tyrosine kinase inhibitor erdafitinib has been approved for locally advanced or metastatic urothelial cancer with FGFR2/3 alterations. Despite the initial efficacy… read more here.
Keywords: cancer; fgfr; erdafitinib; altered bladder ... See more keywords
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03896-1
Abstract: To characterize the effect of erdafitinib on electrocardiogram (ECG) parameters and the relationship between erdafitinib plasma concentrations and QTc interval changes in patients with advanced or refractory solid tumors. Triplicate ECGs and continuous 12-lead Holter… read more here.
Keywords: qtc; ecg; analysis; effect ... See more keywords
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-024-02583-3
Abstract: In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8 months) and reduced risk of death by 36% (hazard ratio 0.64, P = 0.005) compared with chemotherapy in metastatic… read more here.
Keywords: metastatic urothelial; erdafitinib; subgroup analysis; japanese subgroup ... See more keywords
Erdafitinib exerts the anticancer effect on urothelial carcinoma via induction of authophagy.
Sign Up to like & getrecommendations! Published in 2020 at "Die Pharmazie"
DOI: 10.1691/ph.2020.9911
Abstract: Erdafitinib has recently been approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC). The current study aimed to evaluate whether erdafitinib inhibits the proliferation in UC via inducing authophagy.… read more here.
Keywords: showed erdafitinib; authophagy; urothelial carcinoma; cell ... See more keywords